AI Scientists, Stock Tumble, Patent Lawsuit, and New Partnerships

Agentic AI is growing in its applications. Google Deep Mind and Edison are leveraging the growing capabilities by developing AI Scientists. These platforms are poised to streamline the scientific process, aiding human scientists with a variety of tasks. Meanwhile, despite positive data in its Phase III DMD therapy trial, Regenxbio’s stock fell for a variety of reasons. 10X Genomics and Harvard University are suing Element Biosciences over patents for a multiomics platform. Finally, Bristol Meyers Squibb is partnering with Hengrui Pharma to develop 13 early-stage programs with the potential to grow their investment to a predicted $15 billion in sales.  Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news.  Listed below are links to the GEN stories referenced in this episode of Touching Base:  Google DeepMind and Edison Are Building the AI Scientist By Fay Lin, PhD, GEN Edge, May 19, 2026StockWatch: Regenxbio Tumbles Despite Positive Pivotal Data for DMD Gene Therapy CandidateBy Alex Philippidis, GEN Edge, May 17, 2026 10x Genomics, Harvard Target Element’s Multiomics Platform in Patent Lawsuit By Alex Philippidis, GEN Edge, May 12, 2026 BMS, Hengrui Pharma Partner on 13 Programs in Up-to-$15.2B Collaboration By Alex Philippidis, GEN Edge, May 13, 2026Touching Base Podcast Hosted by Corinna Singleman, PhD  Behind the Breakthroughs Hosted by Jonathan D. Grinstein, PhD  The State of Precision Medicine SummitJoin us June 3, 2026 Hosted on Acast. See acast.com/privacy for more information.